ONCORAL PHARMA ApS: Financial statements 2020
CVR: 35481214
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
ONCORAL PHARMA ApS (CVR 35481214) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -3,856,439 and a net result of DKK -3,458,277 compared with DKK -1,462,439 the year before. Equity in the 2020 report amounted to DKK -5,440,053.
- Gross Profit
- DKK -3,856,439
- Profit/Loss
- DKK -3,458,277
- Equity
- DKK -5,440,053
- Total Assets
- DKK 2,721,729
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -3.9 mio. | -3.5 mio. | -5.4 mio. | - |
| 2019 | - | -1.6 mio. | -1.5 mio. | -1.4 mio. | - |
| 2016 | - | -419 t. | -935 t. | -4.5 mio. | 0 |
| 2015 | - | -997 t. | -1 mio. | -3.6 mio. | 0 |
Official annual report
How creditworthy is ONCORAL PHARMA ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
ONCORAL PHARMA ApS has published its interim report for the period July 1, 2019 – December 31, 2019.
About ONCORAL PHARMA ApS
ONCORAL PHARMA ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2013. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Magnus Olafsson Corfitzen. The company is owned by Ascelia Pharma AB. The company has 0 employees (2014). In 2025, the company reported a gross profit of DKK -1,617,542 and a net result of DKK -2,313,169 compared with DKK -4,057,834 the year before. Equity in the 2025 report amounted to DKK -35,503,290.